<code id='3042F23CB6'></code><style id='3042F23CB6'></style>
    • <acronym id='3042F23CB6'></acronym>
      <center id='3042F23CB6'><center id='3042F23CB6'><tfoot id='3042F23CB6'></tfoot></center><abbr id='3042F23CB6'><dir id='3042F23CB6'><tfoot id='3042F23CB6'></tfoot><noframes id='3042F23CB6'>

    • <optgroup id='3042F23CB6'><strike id='3042F23CB6'><sup id='3042F23CB6'></sup></strike><code id='3042F23CB6'></code></optgroup>
        1. <b id='3042F23CB6'><label id='3042F23CB6'><select id='3042F23CB6'><dt id='3042F23CB6'><span id='3042F23CB6'></span></dt></select></label></b><u id='3042F23CB6'></u>
          <i id='3042F23CB6'><strike id='3042F23CB6'><tt id='3042F23CB6'><pre id='3042F23CB6'></pre></tt></strike></i>

          fashion

          fashion

          author:Wikipedia    Page View:73

          Who polices algorithms? How would you name the first approved CRISPR medicine? And what pairs well with a biotech downturn?

          We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. Our colleague Casey Ross joins us to tell the bombshell story of how the nation’s largest health insurer used a computer algorithm to deny patient care and boost its profitability. Then, biotech veteran Michael Gilman calls in to offer a behind-the-scenes peek at what it’s like to be a startup CEO in this economic downturn — and which cocktail recipes help make it bearable. We also discuss a pioneering approval for a genome-editing medicine.

          advertisement

          For more on what we cover, here’s the UnitedHealth story; here’s more on the CRISPR approval; here’s where you can find episodes of Color Code; here’s where you can subscribe to the First Opinion Podcast; and here’s where you can subscribe to our biotech newsletter, The Readout.

          Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

          And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

          advertisement

          focus

          Novavax promises a turnaround & Lilly roils the obesity market
          Novavax promises a turnaround & Lilly roils the obesity market

          SammyKimballforSTATCanNovavaxfinallygetitright?What’sa“triple-G”drug?AndisNovoNordisklosingground?We

          read more
          Reframing the conversation around gain
          Reframing the conversation around gain

          DebatesoverCovid'soriginshavebroughtnewattentiontotherisksofgain-of-functionresearch,butnotthebenefi

          read more
          Jerome Adams on the need for new antivirals for Covid
          Jerome Adams on the need for new antivirals for Covid

          PaxlovidtabletsamplesbeinginspectedinFreiburg,Germany.PfizerviaAPTheU.S.Covid-19Public HealthEmergen

          read more

          FDA clears Verve to begin U.S. study of gene

          AdobeVerveTherapeuticssaidMondaythatithadreceivedclearancefromtheFoodandDrugAdministrationtoconducta